Fate therapeutics reports positive interim data from its phase 1 study of ft516 in combination with rituximab for b-cell lymphoma

3 of 4 patients evaluable for efficacy in dose escalation cohorts 2 and 3 show objective response, with 2 patients achieving complete response

FATE Ratings Summary

FATE Quant Ranking